Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
MAP kinase signaling
Protein [2]
GTPase HRas, N-terminally processed
Synonyms [1]

HRAS (Harvey rat sarcoma viral oncogene homolog) encodes the GTPase HRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. HRAS is implicated in the pathogenesis of several cancers.


HRAS is altered in 0.94% of all cancers with bladder urothelial carcinoma, breast invasive ductal carcinoma, lung adenocarcinoma, prostate adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].

HRAS GENIE Cases - Top Diseases

The most common alterations in HRAS are HRAS Mutation (0.77%), HRAS Missense (0.75%), HRAS Exon 2 Mutation (0.30%), HRAS Codon 61 Missense (0.26%), and HRAS Q61R (0.14%) [3].

HRAS GENIE Cases - Top Alterations

Significance of HRAS in Diseases

Malignant Solid Tumor +

Colorectal Carcinoma +

Non-Small Cell Lung Carcinoma +

Melanoma +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Chronic Myelomonocytic Leukemia +

Non-Hodgkin Lymphoma +

Thyroid Gland Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Squamous Cell Lung Carcinoma +

Ovarian Carcinoma +

Poorly Differentiated Thyroid Gland Carcinoma +

Squamous Cell Carcinoma +

Small Cell Lung Carcinoma +

Cancer +

Glioma +

Low Grade Glioma +

Pancreatic Carcinoma +

Acute Lymphoblastic Leukemia +

Histiocytic And Dendritic Cell Neoplasm +

Multiple Myeloma +

Neurofibromatosis Type 1 +

Pancreatic Ductal Adenocarcinoma +

Thyroid Gland Follicular Carcinoma +

Embryonal Rhabdomyosarcoma +

Malignant Thyroid Gland Neoplasm +

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +

Thymic Carcinoma +

Urothelial Carcinoma +

Thyroid Gland Papillary Carcinoma +

Cutaneous Melanoma +

Mucosal Melanoma +

Endometrial Carcinoma +

Malignant Peripheral Nerve Sheath Tumor +

Neuroblastoma +

Prostate Carcinoma +

Soft Tissue Sarcoma +

Breast Carcinoma +

Colorectal Adenocarcinoma +

Gastric Carcinoma +

Diffuse Large B-Cell Lymphoma +

Diffuse Glioma +

Lung Adenocarcinoma +

Renal Cell Carcinoma +

Astrocytic Tumor +

Hepatocellular Carcinoma +

Myeloid Neoplasm +

Pancreatic Adenocarcinoma +

Lymphoma +

Esophageal Carcinoma +

Cholangiocarcinoma +

Chronic Myeloid Leukemia +

Double-Hit Lymphoma +

Dysembryoplastic Neuroepithelial Tumor +

Gangliocytoma +

Ganglioglioma +

Histiocytosis +

Juvenile Myelomonocytic Leukemia +

Low Grade Ovarian Serous Adenocarcinoma +

Low-Grade Neuroepithelial Tumor, NOS +

Mantle Cell Lymphoma +

Myelodysplastic Syndrome With Excess Blasts-2 +

Neuronal And Mixed Neuronal-Glial Tumors +

Peripheral T-Cell Lymphoma +

Pilocytic Astrocytoma +

Pilomyxoid Astrocytoma +

Rhabdoid Tumor +

Schwannoma +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.